MedTrace Logo

Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial

NCT03037372 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2017-01-31

No results posted yet for this study

Summary

This study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving antiretroviral therapy in an African cohort

Conditions

  • HIV Infection

Interventions

DRUG

ART, Atorvastatin

ART, Atorvastatin

DRUG

ART, Rosuvastatin

ART, Rosuvastatin

DRUG

ART, No statin

ART, No statin

DRUG

Healthy-HIV-negative

Age-matched, Healthy HIV-negative

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Case Western Reserve University

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Damalie Nakanjako, PhD · Makerere University College of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2022-06-30
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037372 on ClinicalTrials.gov